2017
DOI: 10.1007/s40259-017-0238-1
|View full text |Cite
|
Sign up to set email alerts
|

Patients’ Understanding and Attitudes Towards Infliximab and Etanercept Biosimilars: Result of a UK Web-Based Survey

Abstract: Survey participants had a good knowledge and understanding of biosimilars. Participants on biosimilars were confident and positive about biosimilars' safety, efficacy and switching, whereas participants on the originator biologics were more reluctant to switch to biosimilars. Those patients who expressed concerns felt that more clinical trials on switching biosimilars, better communication and reassurance by healthcare professional teams and further involvement in decision making would increase their acceptanc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
26
1

Year Published

2018
2018
2023
2023

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 25 publications
(28 citation statements)
references
References 12 publications
1
26
1
Order By: Relevance
“…A 2014-2015 European survey of 1059 patients with IBD found that approximately 36% had heard of biosimilars [168], and 49% of Belgian patients with RA (surveyed in 2016) reported familiarity with biosimilars [169]. In a 2017 UK survey of patients with RA and AS, 66% and 80% of respondents receiving RPs or biosimilars, respectively, understood what biosimilars were [170]. Among European patients with IBD who had heard of biosimilars, safety and efficacy were the most common concerns (47% and 39%, respectively), whereas around one-quarter of respondents had no specific concerns [168].…”
Section: Patients' Perspective: Improved Information Sharing May Encomentioning
confidence: 99%
“…A 2014-2015 European survey of 1059 patients with IBD found that approximately 36% had heard of biosimilars [168], and 49% of Belgian patients with RA (surveyed in 2016) reported familiarity with biosimilars [169]. In a 2017 UK survey of patients with RA and AS, 66% and 80% of respondents receiving RPs or biosimilars, respectively, understood what biosimilars were [170]. Among European patients with IBD who had heard of biosimilars, safety and efficacy were the most common concerns (47% and 39%, respectively), whereas around one-quarter of respondents had no specific concerns [168].…”
Section: Patients' Perspective: Improved Information Sharing May Encomentioning
confidence: 99%
“…They identified that the majority of patients were satisfied with their current therapy; however, patient concerns regarding biosimilars included not enough knowledge about the therapy, potential side effects, and potential long‐term problems (eg, loss of disease activity control) . Aladul and colleagues reported that patients with RA or AS in their United Kingdom survey who were receiving a biosimilar were optimistic about biosimilars’ safety, efficacy, and switching, whereas patients who were receiving the originator biologic were reluctant to switch to a biosimilar . Peyrin‐Biroulet and colleagues reported from their survey of European patients with inflammatory bowel disease who were receiving the bio‐originator that most patients were not familiar with biosimilars and, of those who were, doubts and concerns about the safety and efficacy of biosimilars were raised .…”
Section: Discussionmentioning
confidence: 99%
“…Although switching studies have identified similar safety and efficacy effects between infliximab and infliximab‐dyyb , and though infliximab‐dyyb offers an efficacious and potentially less expensive treatment option, only a limited number of non‐US studies have evaluated patient perspectives and opinions on the infliximab to infliximab‐dyyb switch . In 2017, Kaiser Permanente Colorado (KPCO), an integrated health care delivery system , implemented an infliximab to infliximab‐dyyb switch in patients with RA, PsA, and/or AS.…”
Section: Introductionmentioning
confidence: 99%
“…No patients or members of the public were involved in this study, but the questions were influenced by the results of the authors’ previously published patients’ web survey. 21 …”
Section: Methodsmentioning
confidence: 99%